- GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, New York, June 6, 2024.Even
- Simply Wall St.
High Insider Ownership Growth Companies On US Exchange May 2024
Amidst a backdrop of economic cooling and fluctuating market conditions, the U.S. stock market has shown resilience with signs that rate cuts could be on the horizon, potentially buoying investor sentiment. In this context, companies with high insider ownership can be particularly compelling as they often signal strong confidence from those closest to the company's operations and future prospects.
- GlobeNewswire
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a minimal impact on Verrica’s cash position Common warts is one of the largest and most underserved patient populations in medical dermatology with a prevalence of ~22M in the U.S. and no FDA approved products; Verrica believes com
